---
title: "Windward Bio Shares Close 68% Above $17 IPO Price"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305521473.md"
description: "Windward Bio's shares closed at $28.50 on its first trading day, representing a 68% increase from its $17 IPO price. The company achieved an approximate market capitalization of $1.69 billion upon listing on the Nasdaq on November 13, 2026."
datetime: "2026-11-14T03:13:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305521473.md)
  - [en](https://longbridge.com/en/news/305521473.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305521473.md)
generator: "portal-rs"
---

# Windward Bio Shares Close 68% Above $17 IPO Price

Windward Bio priced its IPO at $17.00 per share and closed its first trading day at $28.50, up 68% from the IPO price. The company had an approximately $1.69B market capitalization.

**Material Details**

| # | Detail                                            | AI Analyst View                                                                                                               |
| - | ------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------- |
| 1 | First-day close $28.50, up 68% from $17 IPO price | The sharp first-day gain signals strong initial trading demand; sustained trading will show whether the premium holds.        |
| 2 | Market capitalization approximately $1.69B        | This is the stated valuation at the first-day close; the release provides no comparison with a prior public-market valuation. |
| 3 | Listed on Nasdaq on Nov. 13, 2026                 | The listing gives investors public-market access to a clinical-stage biotech; its pipeline remains in clinical development.   |

**Context by AI Analyst**

This is Windward Bio's initial public listing, rather than a later confirmation of an established public-market trend. Clinical trial progress and subsequent trading performance would be needed to establish further catalysts.

Based on the original press release from Windward Bio distributed by PR Newswire.

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Summary is based on content distributed by PR Newswire. Please verify any important information with the original source. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [WWB.US](https://longbridge.com/en/quote/WWB.US.md)

## Related News & Research

- [Innovative Immunology Biotech Windward Bio Lists on Nasdaq](https://longbridge.com/en/news/305550818.md)
- [Novo Holdings-backed Windward Bio valued at $1 billion as shares rise in Nasdaq debut](https://longbridge.com/en/news/305492826.md)
- [Windward Bio Raises $50 Million in Private Placement to Sanofi Foreign Participations](https://longbridge.com/en/news/305719353.md)
- [Windward Bio Presents at Jefferies Global Healthcare Conference](https://longbridge.com/en/news/305870877.md)
- [Windward Bio prices $175 million Nasdaq IPO](https://longbridge.com/en/news/305634890.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**